Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Actinium Pharmaceuticals Inc
(NY:
ATNM
)
6.560
-0.500 (-7.08%)
Official Closing Price
Updated: 8:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
April 19, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
April 17, 2024
Via
AB Newswire
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
March 28, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
March 27, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
March 26, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
March 22, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
March 21, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
March 20, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
March 14, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
February 22, 2023
– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of...
Via
FinancialNewsMedia
Actinium Pharmaceuticals’ Shares Stay Bullish Ahead Of Expected Topline Phase 3 Data Release In Q4 ($ATNM)
December 12, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year’s End ($ATNM)
December 08, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 Catalysts ($ATNM)
October 26, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Investor Update Puts Clinical Milestones And Potential Catalysts In The Crosshairs ($ATNM)
October 24, 2022
Via
AB Newswire
Actinium Pharmaceuticals Rally Takes Stock 62% Higher As Its Iomab-B Data Continues To Impress (NYSE AMERICAN: ATNM)
September 29, 2021
Via
AB Newswire
Exposures
Product Safety
Actinium Pharmaceuticals Rally Intact As Its Iomab-B Data Shows 100% Effectiveness In Targeted Patient Population (NYSE AMERICAN: ATNM)
September 23, 2021
Via
AB Newswire
Actinium Pharmaceuticals Stock Jumps 17% Ahead Of SIERRA Trial Update; Iomab-B Shows 100% Effectiveness In Targeted Patient Population (NYSE AMERICAN: ATNM)
September 21, 2021
Via
AB Newswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.